TrialAssure, a leading technology provider advancing clinical trial transparency, disclosure, and data sharing, announced today the opening of TrialAssure B.V., its new European office located in ...

Power Medicine, a company revolutionizing oncology drug development, and AdventHealth, a faith-based health system focused on whole-person care, today announced a strategic collaboration to make ...

San Francisco’s UCSF is stepping into the national spotlight as one of several university medical centers testing whether a ...

Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment ...

Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction ...

Independent Analysis Addresses Common Consumer Questions Including Legitimacy, Safety Considerations, Pricing Transparency, ...

TRADEMARK APPROVALS STRENGTHEN BRAND IDENTITY AND ENHANCE LEGAL PROTECTION NEW YORK CITY, NY, UNITED STATES, January 6, ...

YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic ...

The National Institutes of Health has awarded the Icahn School of Medicine at Mount Sinai an $8.5 million renewal grant to ...

New Financing Supports Disciplined Clinical Execution and Value Creation in Alzheimer's Drug Development - POTOMAC, MARYLAND / ACCESS Newswire / January 5, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ...

The National Institutes of Health has awarded the Icahn School of Medicine at Mount Sinai an $8.5 million renewal grant to continue groundbreaking work aimed at understanding and improving long-term ...

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the ...